Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Earnings live: Cleveland-Cliffs stock slides after revenue miss, Monday.com stock tanks

View original at finance.yahoo.com
Earnings live: Cleveland-Cliffs stock slides after revenue miss, Monday.com stock tanks The fourth quarter earnings season is more than halfway over, and the S&P 500 is on track for solid earnings growth…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • e.l.f.'s value proposition, powerhouse innovation and disruptive marketing engine continue to fuel the brands and the company remains confident in its ability to grow market share and deliver best-in-class growth in beauty

    80% confidence

  • HODL (hold on for dear life)

    80% confidence

  • Strategy's capital structure is stronger and more resilient today than ever before

    80% confidence

  • Despite the continued impact of US tariffs, strong demand supported by product competitiveness has led to increased sales volumes, and Toyota achieved a high level of profit due to price revisions

    80% confidence

  • Monday.com expects first quarter revenue of $338 million to $340 million and operating income of $37 million to $39 million

    80% confidence

  • Peloton expects subscriptions to decrease by 8% year over year to a range of 2.65 million to 2.67 million in fiscal Q3 and revenue between $605 million and $625 million, a 1% decline year over year

    80% confidence

  • Philip Morris expects earnings per share of $7.87 to $8.02 in 2026

    80% confidence

  • Cleveland-Cliffs expects to ship 16.5 million to 17 million tons of steel in 2026

    80% confidence

  • Cleveland-Cliffs performance in 2025 was negatively affected by persistently weak production levels from the automotive sector, an expiring five-year slab contract becoming value-destructive, and a newly adverse dynamic in the Canadian market

    80% confidence

  • As 2026 started, the negative situations affecting Cleveland-Cliffs have all improved

    80% confidence

  • If the 13% EPS growth rate holds, it would represent the 10th consecutive quarter of annual earnings growth for the S&P 500 and the fifth consecutive quarter of double-digit growth

    80% confidence

  • 59% of S&P 500 companies have reported fourth quarter results as of Feb. 6, and Wall Street analysts estimate a 13% increase in earnings per share for the fourth quarter

    80% confidence

  • Three themes emerging from Q4 earnings season: capital expenditures and artificial intelligence, particularly in Big Tech; how companies are thinking about tariffs; and the K-shaped consumer

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Earnings live: Cleveland-Cliffs stock slides after revenue miss, Monday.com stock tanks — Source | Via News | ViaNews EU